Replimune Group (REPL)
(Delayed Data from NSDQ)
$3.46 USD
-2.25 (-39.40%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $3.47 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REPL 3.46 -2.25(-39.40%)
Will REPL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REPL
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for REPL
12 Health Care Stocks Moving In Thursday's Intraday Session
Gold Falls Over 1%; Darden Posts Downbeat Earnings
Replimune (REPL) Engages with FDA on Melanoma Treatment Plan
Replimune (REPL) Evaluates FDA Feedback on Melanoma Treatment
Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more